Header Ads Widget

Responsive Advertisement

Safety Issues of First Adenovirus COVID-19 Vaccine

Phase-1 trial: Adenovirus COVID-19 vaccine found safe, induces immune responses.

A phase-1 trial using a single dose of a vaccine (Ad5-nCoV) that uses a recombinant adenovirus type-5 vector that carries the genetic material that codes for spike glycoprotein of novel coronavirus was found to be safe, well-tolerated and able to generate immune responses against the virus. The adenovirus is a weakened common cold virus.

The trial was carried out on 108 participants aged 18-60 years in Wuhan, China, and had 36 participants each in the low, middle and high-dose groups.

The trial did not involve randomisation of participants and did not have a control arm. The results are based on short duration of follow-up. The results were published in the journal The Lancet.
Currently, there are more than 100 candidate COVID-19 vaccines in development worldwide. A study of COVID-19 vaccine to reach phase 1 clinical trial has found it to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans.The findings of the research have been published in the LANCET .The creation of an effective vaccine is seen as the long-term solution to controlling the COVID-19 pandemic.


Post a Comment